116 related articles for article (PubMed ID: 38795962)
1. A Feasible Estimation of a "Corrected" EQ-5D Social Tariff.
Abellan-Perpiñan JM; Martinez-Perez JE; Sanchez-Martinez FI; Pinto-Prades JL
Value Health; 2024 May; ():. PubMed ID: 38795962
[TBL] [Abstract][Full Text] [Related]
2. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
Kiadaliri AA; Eliasson B; Gerdtham UG
Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of EQ-5D-3L health utility scores using five country-specific tariffs in a rural population aged 45-69 years in Hua county, Henan province, China.
Wang H; Cao C; Guo C; He Y; Li F; Xu R; Liu M; Liu Z; Pan Y; Liu F; Liu Y; Li J; Cai H; He Z; Ke Y
Health Qual Life Outcomes; 2020 Jul; 18(1):228. PubMed ID: 32660494
[TBL] [Abstract][Full Text] [Related]
4. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
5. Adjustment of foreign EQ-5D-3L utilities can increase their transferability.
Oddershede L; Petersen KD
Clinicoecon Outcomes Res; 2015; 7():629-36. PubMed ID: 26719715
[TBL] [Abstract][Full Text] [Related]
6. Quality-of-life valuations of advanced breast cancer by New Zealand women.
Milne RJ; Heaton-Brown KH; Hansen P; Thomas D; Harvey V; Cubitt A
Pharmacoeconomics; 2006; 24(3):281-92. PubMed ID: 16519549
[TBL] [Abstract][Full Text] [Related]
7. Comparison of EQ-5D-5L health state utilities using four country-specific tariffs on a breast cancer patient sample in mainland China.
Liu L; Li S; Wang M; Chen G
Patient Prefer Adherence; 2017; 11():1049-1056. PubMed ID: 28706443
[TBL] [Abstract][Full Text] [Related]
8. Estimating an exchange rate between the EQ-5D-3L and ASCOT.
Stevens K; Brazier J; Rowen D
Eur J Health Econ; 2018 Jun; 19(5):653-661. PubMed ID: 28623464
[TBL] [Abstract][Full Text] [Related]
9. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
Little MH; Reitmeir P; Peters A; Leidl R
Value Health; 2014 Jun; 17(4):364-71. PubMed ID: 24968996
[TBL] [Abstract][Full Text] [Related]
10. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
11. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
[TBL] [Abstract][Full Text] [Related]
12. Utilities of the EQ-5D: transferable or not?
Knies S; Evers SM; Candel MJ; Severens JL; Ament AJ
Pharmacoeconomics; 2009; 27(9):767-79. PubMed ID: 19757870
[TBL] [Abstract][Full Text] [Related]
13. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
14. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
[TBL] [Abstract][Full Text] [Related]
15. In search of a 'pan-European value set'; application for EQ-5D-3L.
Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH
BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625
[TBL] [Abstract][Full Text] [Related]
16. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
Karlsson JA; Nilsson JÅ; Neovius M; Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2011 Dec; 70(12):2163-6. PubMed ID: 21859684
[TBL] [Abstract][Full Text] [Related]
17. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
18. A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample.
Mozzi A; Meregaglia M; Lazzaro C; Tornatore V; Belfiglio M; Fattore G
Clinicoecon Outcomes Res; 2016; 8():267-74. PubMed ID: 27358571
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
20. Efficient Designs for Valuation Studies That Use Time Tradeoff (TTO) Tasks to Map Latent Utilities from Discrete Choice Experiments to the Interval Scale: Selection of Health States for TTO Tasks.
Che M; Pullenayegum E
Med Decis Making; 2023 Apr; 43(3):387-396. PubMed ID: 36866604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
